Introduction: Chronic inflammation may be important in prostate carcinogenesis. Several
Introduction
There is increasing evidence which suggests that chronic inflammation is important in prostate carcinogenesis (1, 2) . Prostatitis has been associated with prostate cancer risk and proliferative inflammatory atrophy of the prostate, a condition marked by chronic inflammation, may be an early precursor lesion for prostate cancer (1, 2) . Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-cancer properties in vitro and in vivo (3, 4) , in support of epidemiologic studies which have shown reductions in prostate cancer risk for aspirin use in particular (5) . Many epidemiologic studies of NSAID use and prostate cancer risk, however, are limited by short-term measurement of NSAID use and most do not adjust for indications of use.
Here we examine the association of long-term NSAID use with prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort study.
Methods

Study Population
Participants were male members of the VITAL cohort (6) 
Statistical Analysis
We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) for total prostate cancer and prostate cancer by grade in relation to NSAID use with Cox proportional hazards regression models, using participants' age as the time metric. Prostate cancer risk factors as well as potential indications for NSAID use were identified a priori for adjustment in multivariable models (see footnote b of Table 1 ). P-values for trend were calculated by treating categorical variables as ordinal in the models. We calculated minimum detectable risks (MDR)
given 80% power (7) . For comparisons of use to non-use of each NSAID, we had an MDR of 
Results
Use of NSAIDs was not associated with total prostate cancer risk (Table 1) . When the analysis was stratified by prostate cancer grade ( 
Risk in the VITamins
